A Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.

Official title

A Randomized, Double-blind, Placebo Controlled, Parallel Study to Determine Safety, Pharmakokinetics and Efficacy of the Different Doses of VL-SE-01 in Healthy Participants.

Overview

The present study is a randomized, placebo-controlled, parallel study. 250 participants will be screened, and considering a screening failure rate of 20%, approximately 200 participants will be randomized in a ratio of 1:1:1:1:1 to receive either different doses of VL-SE-01 or placebo and will be assigned a unique randomization code. Each group will have at least 30 participants (total 150 completers) after accounting for a dropout/withdrawal rate of 25%. The intervention duration for all the study participants is 180 days.

Interventions

• Dietary supplement CBD Isolate (25 mg/0.5 ml)
  0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
• Dietary supplement CBD Isolate (40 mg/0.5 ml)
  0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
• Dietary supplement CBD Isolate (50 mg/0.5 ml)
  0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
• Dietary supplement CBD Broad Extract (50 mg/0.5 ml)
  0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.
• Dietary supplement Placebo
  0.5 ml sublingually to be consumed after dinner, 30 min ± 5 mins before going to bed.

Primary outcome measures

• To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day -5 to Day -1]
• To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 90]
• To evaluate the safety of VL-SE-01 by assessing Fasting Blood Glucose as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 180]
• To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day -5 to Day -1]
• To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 90]
• To evaluate the safety of VL-SE-01 by assessing Renal function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 180]
• To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day -5 to -1]
• To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 90]
• To evaluate the safety of VL-SE-01 by assessing Liver function as part of the Complete Metabolic Panel (CMP) before and after IP consumption. [Time frame: Day 180]

Secondary outcome measures (12)

• To assess the safety and tolerability of VL-SE-01 using blood, which includes Complete Blood Count (CBC). [Time frame: Day -5 to Day -1, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using blood, which includes Inflammation by analyzing CRP levels. [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using blood, which includes Hormonal profile (Luteinizing hormone (LH), follicle-stimulating hormone (FSH), testosterone, estradiol and progesterone) [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using blood, which includes Thyroid profile (T3, T4, TSH) [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using blood, which includes Lipid Profile as assessed by levels of total cholesterol, LDL, HDL and triglycerides [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 on Semen. [Time frame: Day -5 to Day -1 and Day 180]
• To assess the safety and tolerability of VL-SE-01 using blood Plasma levels of CBD and its metabolites [7-Carboxy-cannabidiol (7-COOH-CBD) and 7-Hydroxy-cannabidiol (7-OH-CBD)] [Time frame: Day 195 (single timepoint)]
• To assess the safety and tolerability of VL-SE-01 on Blood Pressure. [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 on Pulse Rate. [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using Electrocardiogram. [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To assess the safety and tolerability of VL-SE-01 using Treatment emergent Adverse Events (TEAEs). [Time frame: Day 0, Day 90, Day 180 and Day 195]
• To evaluate the efficacy of VL-SE-01 on the basis of Incidence of gastrointestinal dysfunction using Structured Assessment of Gastrointestinal Symptoms (SAGIS) questionnaire. [Time frame: Day 0, Day 90, and Day 180]

Eligibility criteria

Inclusion criteria

• Male \& female individuals must be 18 to 55 years of age inclusive, at the time of signing the informed consent.
• Individuals who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
• Individual has a body weight of at least 50 kg (males) or 45 kg (females) and body mass index (BMI) within the range 18.5 to 29.9 kg/m2 (inclusive)
• Individuals with a stressed lifestyle as assessed by PSS scores within 27- 40.
• A male must agree to use contraception during the intervention period and for at least 7 days after the last dose of study intervention and refrain from donating sperm during this period.
• A female is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies:

• Not a woman of childbearing potential (WOCBP)
• OR agrees to use the contraceptive during the intervention period and for at least 90 days after the last dose of study intervention

Exclusion criteria

• Individual has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinology related, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention, or interfering with the interpretation of data.
• Males who has a history of oligospermia, vasectomy and other sperm abnormalities.
• Females who have irregularity or problems in menstrual cycles or diagnosed with polycystic ovarian syndrome.
• Individuals with Type 1 and Type 2 Diabetes mellitus and on medication.
• Individuals with SBP ≥ 160 mmHg and DBP ≥ 100 mmHg.
• Individuals on anti-hypertensives.
• History and/or current cases of chronic alcohol consumption or heavy drinkers as defined by:

• For men, consuming more than 4 drinks on any day or more than 14 drinks/week
• For women, consuming more than 3 drinks on any day or more than 7 drinks/week
• Peri and post-menopausal women with no menstrual cycle in the last 6 months
• Individuals with a history or actively under the influence of Hemp or CBD products by any means of administration
• Individual has a known hypersensitivity to any components of the study medication or comparative drugs (and/or an investigational device) as stated in this protocol
• Individual has a history of unexplained syncope or a family history of sudden death due to long QT syndrome
• Individual with a history and/or currently diagnosed of cancer like lymphoma, leukaemia, or any malignancy.
• Individual has past or intended use of prohibited medication or prescription medication including herbal medications within 2 weeks or 5 half-lives prior to dosing
• Individuals have taken sleep medication within 2 weeks prior to screening
• Individual has used hepatic enzyme-inducing drugs within 2 months prior to dosing
• Individuals has alanine transaminase (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >1.5 times upper limit of normal (ULN)
• Individual has current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
• Individual has any clinically relevant electrocardiogram (ECG) finding at the Screening Visit or at Baseline
• Individual has a history of human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Other

Study locations

India · 6 centers

• Shivam Hospital — Dombivali
• Dhanwantri Hospital — Pune
• Vedant Multispeciality Hospital — Pune
• Punawale Hospital — Pune
• Vishwaraj Hospital — Pune
• Shree Ashirwad Hospital — Thane

Identifiers

NCT: NCT06473246 · SE/230302/CBD/SS

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗